# A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

> **NCT01306617** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 50 (actual)

## Conditions studied

- Chronic Hepatitis C Infection
- Hepatitis C
- Hepatitis C Virus

## Interventions

- **DRUG:** ABT-450
- **DRUG:** ABT-333
- **DRUG:** ribavirin
- **DRUG:** ritonavir

## Key facts

- **NCT ID:** NCT01306617
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-11
- **Final completion:** 2012-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01306617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01306617, "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01306617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*